Joel McComb is Senior Vice President & General Manager of Illumina's Life Sciences Business, and is responsible for managing all products and services related to the research market, namely the BeadArray, BeadXpress, and Sequencing product lines.
Joel joins Illumina from GE Healthcare where he held a number of executive positions including his most recent position as President of the Interventional Medicine Business. Responsible for a $700 million division of GE Healthcare, the Interventional Medicine group provided a broad collection of products for the hospital Interventional Operating Suite and physician's office with applications in Cardiology, Neurology, and Oncology. Prior to this role, Joel was President of Life Sciences Discovery Systems, a $600 million division at GE Healthcare. This business unit was formed after GE acquired Amersham Biosciences, and markets molecular biology, genomics, proteomic, and cellular imaging products. In this role Joel had responsibility for product development, manufacturing, service, global sales and marketing, information systems, quality, business development, and program management.
From 2001 to 2004 Joel was President, Chief Executive Officer, and Board member of Innovadyne Technologies. He was responsible for the strategy and implementation of all operations, beginning with the startup of Innovadyne through its subsequent sale as a profitable business to Gilson, Inc. Prior to his tenure at Innovadyne, Joel held various positions at Beckman Coulter, including roles as General Manager of the Primary Care Diagnostic Division and Director of Corporate Business Development. As General Manager, Joel was responsible for leading Beckman Coulter's $100 million Primary Care Diagnostics Division, which included the former SmithKline Diagnostics businesses. |